Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy
PHASE2CompletedINTERVENTIONAL
Enrollment
14
Participants
Timeline
Start Date
March 22, 2018
Primary Completion Date
July 15, 2020
Study Completion Date
July 15, 2021
Conditions
Prostate Cancer
Interventions
DRUG
radium-223 dichloride
6 doses of Radium-223
Trial Locations (1)
H3T 1E2
Jewish General Hospital, Montreal
All Listed Sponsors
lead
Sir Mortimer B. Davis - Jewish General Hospital
OTHER
NCT03062254 - Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy | Biotech Hunter | Biotech Hunter